Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur Sells 5,209 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30. Following the completion of the transaction, the chief operating officer now directly owns 129,690 shares in the company, valued at $998,613. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Daniel Lesueur also recently made the following trade(s):

• On Thursday, October 3rd, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12.
• On Wednesday, September 4th, Daniel Lesueur sold 8,137 shares of Health Catalyst stock. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $8.86 on Friday. The firm’s 50 day simple moving average is $8.01 and its 200 day simple moving average is $7.11. Health Catalyst, Inc. has a one year low of $5.42 and a one year high of $11.41. The company has a market cap of $535.76 million, a PE ratio of -5.91 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The business had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. During the same period last year, the company earned ($0.21) EPS. The firm’s revenue was up 3.7% compared to the same quarter last year. Equities research analysts expect that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HCAT shares. Royal Bank of Canada raised their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday. Piper Sandler reduced their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Evercore ISI increased their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. JPMorgan Chase & Co. increased their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Health Catalyst presently has an average rating of “Moderate Buy” and an average price target of $11.64.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Primecap Management Co. CA raised its holdings in Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock worth $15,205,000 after purchasing an additional 305,079 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in shares of Health Catalyst in the 1st quarter valued at $8,780,000. Acadian Asset Management LLC increased its stake in shares of Health Catalyst by 38.3% in the 1st quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after acquiring an additional 200,494 shares in the last quarter. ClariVest Asset Management LLC increased its stake in shares of Health Catalyst by 303.9% in the 1st quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company’s stock valued at $2,126,000 after acquiring an additional 212,425 shares in the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Health Catalyst in the 3rd quarter valued at $2,012,000. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.